Dermatomyositis bei Kindern und Jugendlichen

Living reference work entry
First Online: 29 April 2021

pp 1–37
Cite this living reference work entry

Pädiatrische Rheumatologie

Claas Hinze⁴ &
Angelika Thon⁵

Part of the book series: Springer Reference Medizin ((SRM))

68 Accesses

Zusammenfassung

Die juvenile Dermatomyositis (JDM) zählt zu den schwerwiegendsten rheumatischen Erkrankungen des Kindesalters. Dies beruht auf der oft starken Beeinträchtigung der Patienten aufgrund der entzündlichen Beteiligung von Haut, Muskulatur, kleinsten Gefäßen und Organen und auf dem hohen Risiko für die Entwicklung von Spätfolgen, inkl. dystropher Kalzifizierung, Kontrakturen, Lipodystrophie und Glucocorticoid-Nebenwirkungen. Die charakteristischen Hautveränderungen sind meistens pathognomonisch und essenziell für die Diagnosestellung. Zu den hilfreichen diagnostischen Verfahren zählen außerdem die Bestimmung von Muskelenzymen, die Magnetresonanztomografie der Muskulatur und der Nachweis von myositisspezifischen Antikörpern. Um das Auftreten von Spätfolgen zu vermeiden, ist eine rasch wirksame, zielgerichtete Therapie anzustreben. Hierzu werden neben Glucocorticoiden verschiedene glucocorticoidsparende Medikamente erfolgreich eingesetzt

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Dermatomyositis bei Kindern und Jugendlichen

Chapter © 2022

Juvenile Dermatomyositis

Chapter © 2020

Juvenile Dermatomyositis

Chapter © 2019

Literatur

Abdul-Aziz R, Yu CY, Adler B, Bout-Tabaku S, Lintner KE, Moore-Clingenpeel M, Spencer CH (2017) Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM). Pediatr Rheumatol Online J 15(1):25. https://doi.org/10.1186/s12969-017-0154-4
Article PubMed PubMed Central Google Scholar
Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145–1156. https://doi.org/10.1007/s00198-019-04906-x
Article CAS PubMed Google Scholar
Aeschlimann FA, Fremond ML, Duffy D, Rice GI, Charuel JL, Bondet V, Saire E, Neven B, Bodemer C, Balu L, Gitiaux C, Crow YJ, Bader-Meunier B (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain J Neurol 141(11):e80. https://doi.org/10.1093/brain/awy255
Article Google Scholar
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749. https://doi.org/10.1002/art.38270
Article CAS PubMed PubMed Central Google Scholar
Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27(10):2498–2503
CAS PubMed Google Scholar
Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira SJ, Marcantoni MB, Meiorin S, Filocamo G, Pilkington C, Maillard S, Al-Mayouf S, Prahalad S, Fasth A, Joos R, Schikler K, Mozolova D, Landgraf JM, Martini A, Ruperto N, Paediatric Rheumatology International Trials O (2009) Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 61(4):509–517. https://doi.org/10.1002/art.24343
Article PubMed Google Scholar
Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160(3):520–522. https://doi.org/10.1016/j.jpeds.2011.11.057
Article PubMed PubMed Central Google Scholar
Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13(6):249. https://doi.org/10.1186/ar3531
Article CAS PubMed PubMed Central Google Scholar
Banker BQ, Victor M (1966) Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 45(4):261–289. https://doi.org/10.1097/00005792-196607000-00001
Article CAS Google Scholar
Barth Z, Schwartz T, Flato B, Aalokken TM, Koller A, Lund MB, Sjaastad I, Sanner H (2019) Association between nailfold capillary density and pulmonary and cardiac involvement in medium to longstanding juvenile dermatomyositis. Arthritis Care Res (Hoboken) 71(4):492–497. https://doi.org/10.1002/acr.23687
Article CAS Google Scholar
Barth Z, Witczak BN, Flato B, Koller A, Sjaastad I, Sanner H (2018) Assessment of microvascular abnormalities by nailfold capillaroscopy in juvenile dermatomyositis after medium- to long-term followup. Arthritis Care Res (Hoboken) 70(5):768–776. https://doi.org/10.1002/acr.23338
Article Google Scholar
Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94(5):1729–1735. https://doi.org/10.1172/JCI117520
Article CAS PubMed PubMed Central Google Scholar
Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA (2008) A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. Bone 43(6):1101–1107. https://doi.org/10.1016/j.bone.2008.07.245
Article PubMed Google Scholar
Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, Kambayashi T, Koretzky GA (2011) Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 121(6):2264–2277. https://doi.org/10.1172/JCI43157
Article CAS PubMed PubMed Central Google Scholar
Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76(2):329–340. https://doi.org/10.1136/annrheumdis-2016-209247
Article PubMed Google Scholar
Bertolazzi C, Cutolo M, Smith V, Gutierrez M (2017) State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. Semin Arthritis Rheum 47(3):432–444. https://doi.org/10.1016/j.semarthrit.2017.06.001
Article PubMed Google Scholar
Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O‘Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study G (2008) Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87(2):70–86. https://doi.org/10.1097/MD.0b013e31816bc604
Article Google Scholar
Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC (1964) Dermatomyositis. J Pediatr 64:101–131. https://doi.org/10.1016/s0022-3476(64)80325-5
Article CAS PubMed Google Scholar
Bloom BJ, Tucker LB, Miller LC, Schaller JG (1995) von Willebrand factor in juvenile dermatomyositis. J Rheumatol 22(2):320–325
CAS PubMed Google Scholar
Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM (2003) Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 49(1):7–15. https://doi.org/10.1002/art.10924
Article PubMed Google Scholar
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347. https://doi.org/10.1056/NEJM197502132920706
Article CAS PubMed Google Scholar
Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103(6):882–888. https://doi.org/10.1016/s0022-3476(83)80706-9
Article CAS PubMed Google Scholar
Cantez S, Gross GJ, MacLusky I, Feldman BM (2017) Cardiac findings in children with juvenile Dermatomyositis at disease presentation. Pediatr Rheumatol Online J 15(1):54. https://doi.org/10.1186/s12969-017-0182-0
Article PubMed PubMed Central Google Scholar
Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601. https://doi.org/10.1084/jem.20041367
Article CAS PubMed PubMed Central Google Scholar
Castro TC, Lederman H, Terreri MT, Caldana WI, Zanoteli E, Hilario MO (2014) Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients. Scand J Rheumatol 43(4):329–333. https://doi.org/10.3109/03009742.2013.868509
Article CAS PubMed Google Scholar
Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381(3):291–293. https://doi.org/10.1056/NEJMc1900045
Article PubMed Google Scholar
Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM (2008) Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 58(2):571–576. https://doi.org/10.1002/art.23299
Article PubMed PubMed Central Google Scholar
Crowe WE, Bove KE, Levinson JE, Hilton PK (1982) Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 25(2):126–139. https://doi.org/10.1002/art.1780250203
Article CAS PubMed Google Scholar
Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, Guiguonis V, Picherot G, Cimaz R (2012) Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 32(3):711–716. https://doi.org/10.1007/s00296-010-1653-5
Article PubMed Google Scholar
De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A (1993) Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child 69(2):232–235. https://doi.org/10.1136/adc.69.2.232
Article PubMed PubMed Central Google Scholar
Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA, Juvenile Dermatomyositis Research G (2018) Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol 70(5):785–793. https://doi.org/10.1002/art.40418
Article CAS PubMed PubMed Central Google Scholar
Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, NJ MH, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR, Group UKJDR (2016) Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol 68(11):2806–2816. https://doi.org/10.1002/art.39753
Article CAS PubMed PubMed Central Google Scholar
Dolezalova P, Young SP, Bacon PA, Southwood TR (2003) Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 62(5):444–449. https://doi.org/10.1136/ard.62.5.444
Article CAS PubMed PubMed Central Google Scholar
Dourmishev LA, Durmishev A, Ohio Library and Information Network (2009) Differential Diagnosis of Dermatomyositis. In: Dermatomyositis: advances in recognition, understanding and management. Springer, Berlin/Heidelberg, S xvii, 354 pages
Google Scholar
Dressler F, Frosch M, Monkemoller K, Thon A, Weissbarth-Riedel E, Horneff G (2011) Results of the German ESPED-recording of new patients with juvenile dermatomyositis (JDM). Klin Padiatr 223(5):280–282. https://doi.org/10.1055/s-0031-1273723
Article CAS PubMed Google Scholar
Dressler F, Huppertz HI (2006) Juvenile dermatomyositis. Z Rheumatol 65(7):587–590., 592–584. https://doi.org/10.1007/s00393-006-0109-5
Article CAS PubMed Google Scholar
Duvvuri B, Pachman LM, Morgan G, Khojah AM, Klein-Gitelman M, Curran ML, Doty S, Lood C (2020) Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis. Arthritis Rheumatol 72(2):348–358. https://doi.org/10.1002/art.41078
Article CAS PubMed Google Scholar
Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371(9631):2201–2212. https://doi.org/10.1016/S0140-6736(08)60955-1
Article PubMed Google Scholar
Fioranelli M, Roccia MG, Lotti T (2016) Treatment of dermatomyositis with ruxolitinib. Dermatol Ther 29(4):285. https://doi.org/10.1111/dth.12308
Article PubMed Google Scholar
Fischer TJ, Rachelefsky GS, Klein RB, Paulus HE, Stiehm ER (1979) Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. Am J Dis Child 133(4):386–389. https://doi.org/10.1001/archpedi.1979.02130040040009
Article CAS PubMed Google Scholar
Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29(3–4):307–341. https://doi.org/10.3109/10408369209114604
Article CAS PubMed Google Scholar
Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45(5):676–683. https://doi.org/10.1002/mus.23302
Article PubMed Google Scholar
Galarraga B, Sinclair D, Fahie-Wilson MN, McCrae FC, Hull RG, Ledingham JM (2003) A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review. Rheumatology (Oxford) 42(1):186–188. https://doi.org/10.1093/rheumatology/keg039
Article CAS Google Scholar
Gardner-Medwin JM, Irwin G, Johnson K (2009) MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 1154:52–83. https://doi.org/10.1111/j.1749-6632.2009.04498.x
Article PubMed Google Scholar
Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367(21):2015–2025. https://doi.org/10.1056/NEJMra1009433
Article CAS PubMed Google Scholar
Ghali FE, Stein LD, Fine JD, Burkes EJ, McCauliffe DP (1999) Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135(11):1370–1374. https://doi.org/10.1001/archderm.135.11.1370
Article CAS PubMed Google Scholar
Greenberg SA (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12(3):198–203. https://doi.org/10.1007/s11926-010-0101-6
Article CAS PubMed PubMed Central Google Scholar
Gunawardena H (2017) The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clin Rev Allergy Immunol 52(1):45–57. https://doi.org/10.1007/s12016-015-8513-8
Article CAS PubMed Google Scholar
Guzman J, Petty RE, Malleson PN (1994) Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 21(4):739–743
CAS PubMed Google Scholar
Haas RH, Dyck RF, Dubowitz V, Pepys MB (1982) C-reactive protein in childhood dermatomyositis. Ann Rheum Dis 41(5):483–485. https://doi.org/10.1136/ard.41.5.483
Article CAS PubMed PubMed Central Google Scholar
Hassan J, van der Net JJ, van Royen-Kerkhof A (2008) Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 27(11):1469–1471. https://doi.org/10.1007/s10067-008-0973-2
Article PubMed Google Scholar
Hecken J (2013) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage VI – Off-Label-Use Intravenöse Immunglobuline (IVIG) bei Polymyositis und bei Dermatomyositis. In: Bd J (Hrsg) BAnz AT 09.07.2013 B1. Bundesanzeiger
Google Scholar
Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR (1993) MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 161(2):359–366. https://doi.org/10.2214/ajr.161.2.8333378
Article CAS PubMed Google Scholar
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100. https://doi.org/10.1016/S0140-6736(00)03540-6
Article CAS PubMed Google Scholar
Hinze C, Gohar F, Foell D (2015) Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol 11(5):290–300. https://doi.org/10.1038/nrrheum.2014.212
Article CAS PubMed Google Scholar
Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth F, Lainka E, Brunner J, Fesq H, Foell D, Muller-Felber W, Neudorf U, Rietschel C, Schwarz T, Schara U, Haas JP (2018a) Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online J 16(1):40. https://doi.org/10.1186/s12969-018-0257-6
Article PubMed PubMed Central Google Scholar
Hinze CH, Speth F, Oommen PT, Haas JP (2018b) Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. Pediatr Rheumatol Online J 16(1):38. https://doi.org/10.1186/s12969-018-0256-7
Article PubMed PubMed Central Google Scholar
Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG (2014) The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 16(12):467. https://doi.org/10.1007/s11926-014-0467-y
Article CAS PubMed PubMed Central Google Scholar
Hornig J, Weinhage T, Schmidt LH, Buerke B, Schneider U, Pavenstadt H, Becker H, Gabriels G (2018) Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol 77(10):952–957. https://doi.org/10.1007/s00393-018-0565-8
Article CAS PubMed Google Scholar
Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371(26):2537–2538. https://doi.org/10.1056/NEJMc1412997
Article PubMed Google Scholar
Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7(6):441–446. https://doi.org/10.1007/s11926-005-0048-1
Article PubMed Google Scholar
Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM (2010) Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children‘s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 62(2):219–225. https://doi.org/10.1002/acr.20071
Article CAS Google Scholar
Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, Kahn P, Rahimi H, Robinson AB, Vehe RK, Weiss JE, Spencer C, Juvenile Dermatomyositis Research Committee of the Childhood A, Rheumatology Research A (2017) Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol 44(1):110–116. https://doi.org/10.3899/jrheum.160688
Article CAS PubMed Google Scholar
Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C, Juvenile Dermatomyositis Subcommittee of the Childhood A, Rheumatology Research A (2012) Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 64(4):546–553. https://doi.org/10.1002/acr.20695
Article Google Scholar
Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, Chanoine JP, Petty RE (2001) Lipodystrophy in patients with juvenile dermatomyositis – evaluation of clinical and metabolic abnormalities. J Rheumatol 28(3):610–615
CAS PubMed Google Scholar
Hughes M, Lilleker JB, Herrick AL, Chinoy H (2015) Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis 74(5):795–798. https://doi.org/10.1136/annrheumdis-2014-206812
Article CAS PubMed Google Scholar
Huppertz HI, Frosch M, Kuhn C, Christen HJ (1998) Treatment of juvenile dermatomyositis (JDM) with high-dose oral steroids or with steroid-pulse-therapy plus low-dose oral steroids. Arthritis Rheum 41(9 Suppl):S264
Google Scholar
Huybers S, Naber TH, Bindels RJ, Hoenderop JG (2007) Prednisolone-induced Ca²⁺ malabsorption is caused by diminished expression of the epithelial Ca²⁺ channel TRPV6. Am J Physiol Gastrointest Liver Physiol 292(1):G92–G97. https://doi.org/10.1152/ajpgi.00317.2006
Article CAS PubMed Google Scholar
Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International M, Clinical Studies G (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54. https://doi.org/10.1093/rheumatology/keg427
Article CAS Google Scholar
Jacobs JC (1977) Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics 59(2):212–218
CAS PubMed Google Scholar
Janis JF, Winkelmann RK (1968) Histopathology of the skin in dermatomyositis. A histopathologic study of 55 cases. Arch Dermatol 97(6):640–650
Article CAS PubMed Google Scholar
Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B, Vignery A, Eisenbarth SC, Flavell RA (2011) NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci U S A 108(36):14867–14872. https://doi.org/10.1073/pnas.1111101108
Article PubMed PubMed Central Google Scholar
Kato M, Ikeda K, Kageyama T, Kasuya T, Kumagai T, Furuya H, Furuta S, Tamachi T, Suto A, Suzuki K, Nakajima H (2019) Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with Anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol. https://doi.org/10.1097/rhu.0000000000000984
Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP (2009) Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 60(6):1825–1830. https://doi.org/10.1002/art.24571
Article PubMed PubMed Central Google Scholar
Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, Schikler K, Curran ML, Barillas-Arias L, Spencer CH, Rider LG, Huber AM (2017) Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J 15(1):1. https://doi.org/10.1186/s12969-016-0134-0
Article PubMed PubMed Central Google Scholar
Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, Rider LG (2000) Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 43(8):1866–1873. https://doi.org/10.1002/1529-0131(200008)43:8<1866::AID-ANR24>3.0.CO;2-6
Article CAS PubMed Google Scholar
Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL (2017) Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken) 69(7):1088–1094. https://doi.org/10.1002/acr.23113
Article CAS Google Scholar
Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158(4):675–677. https://doi.org/10.1016/j.jpeds.2010.11.033
Article CAS PubMed Google Scholar
Kobayashi I, Ono S, Kawamura N, Okano M, Kobayashi K (2001) Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis. Pediatrics Int Off J Jpn Pediatr Soci 43(1):109–111. https://doi.org/10.1046/j.1442-200x.2001.01367.x
Article CAS Google Scholar
Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 54(5):784–791. https://doi.org/10.1093/rheumatology/keu385
Article CAS Google Scholar
Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, Arima M, Maezawa R (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114–2119. https://doi.org/10.1093/rheumatology/key188
Article CAS Google Scholar
Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, Vleugels RA (2016) Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol 152(8):944–945. https://doi.org/10.1001/jamadermatol.2016.0866
Article PubMed Google Scholar
Ladd PE, Emery KH, Salisbury SR, Laor T, Lovell DJ, Bove KE (2011) Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 197(1):W153–W158. https://doi.org/10.2214/AJR.10.5337
Article PubMed Google Scholar
Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y (2018) JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain J Neurol 141(6):1609–1621. https://doi.org/10.1093/brain/awy105
Article Google Scholar
Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM (2011) Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 70(12):2089–2094. https://doi.org/10.1136/ard.2011.153718
Article CAS PubMed Google Scholar
Laskin BL, Choyke P, Keenan GF, Miller FW, Rider LG (1999) Novel gastrointestinal tract manifestations in juvenile dermatomyositis. J Pediatr 135(3):371–374. https://doi.org/10.1016/s0022-3476(99)70137-x
Article CAS PubMed Google Scholar
Lebastchi J, Ajluni N, Neidert A, Oral EA (2015) A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin. J Clin Endocrinol Metab 100(11):3967–3970. https://doi.org/10.1210/jc.2015-2589
Article CAS PubMed PubMed Central Google Scholar
Lee-Kirsch MA (2017) The type i interferonopathies. Annu Rev Med 68:297–315. https://doi.org/10.1146/annurev-med-050715-104506
Article CAS PubMed Google Scholar
Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF (2010) Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr 156(2):302–307. https://doi.org/10.1016/j.jpeds.2009.09.008
Article CAS PubMed Google Scholar
Li D, Tansley SL (2019) Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep 21(12):74. https://doi.org/10.1007/s11926-019-0871-4
Article PubMed PubMed Central Google Scholar
Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ, Endo Y, Komaki H, Fujii T, Kawano Y, Mori-Yoshimura M, Oya Y, Xi J, Zhu W, Zhao C, Watanabe Y, Ikemoto K, Nishikawa A, Hamanaka K, Mitsuhashi S, Suzuki N, Nishino I (2017) Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford) 56(2):287–293. https://doi.org/10.1093/rheumatology/kew386
Article Google Scholar
Linos E, Keiser E, Kanzler M, Sainani KL, Lee W, Vittinghoff E, Chren MM, Tang JY (2012) Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. Cancer Causes Control 23(1):133–140. https://doi.org/10.1007/s10552-011-9862-0
Article PubMed Google Scholar
Livermore P, Gray S, Mulligan K, Stinson JN, Wedderburn LR, Gibson F (2019) Being on the juvenile dermatomyositis rollercoaster: a qualitative study. Pediatr Rheumatol Online J 17(1):30. https://doi.org/10.1186/s12969-019-0332-7
Article PubMed PubMed Central Google Scholar
Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, Hicks JE, Levinson JE, Mier R, Pachman LM, Passo MH, Perez MD, Reed AM, Schikler KN, Smith M, Zemel LS, Rider LG (1999) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 42(10):2213–2219. https://doi.org/10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8
Article CAS PubMed Google Scholar
Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O‘Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
Article PubMed Google Scholar
Maillard SM, Jones R, Owens CM, Pilkington C, Woo PM, Wedderburn LR, Murray KJ (2005) Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 53(4):558–564. https://doi.org/10.1002/art.21332
Article PubMed Google Scholar
Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, Viola S, Buoncompagni A, Mattiuz C, Beltramo A, Consolaro A, Ravelli A, Ruperto N, Picco P, Magnano GM, Martini A (2014) Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis 73(6):1083–1090. https://doi.org/10.1136/annrheumdis-2012-202915
Article PubMed Google Scholar
Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G (2013) Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken) 65(12):1969–1975. https://doi.org/10.1002/acr.22088
Article CAS Google Scholar
Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G (2018) Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford) 57(11):1956–1963. https://doi.org/10.1093/rheumatology/key190
Article CAS Google Scholar
Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD (2017) Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology (Oxford) 56(8):1342–1347. https://doi.org/10.1093/rheumatology/kex162
Article Google Scholar
Martin N, Krol P, Smith S, Beard L, Pilkington CA, Davidson J, Wedderburn LR, Juvenile Dermatomyositis Research G (2012) Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken) 64(11):1665–1672. https://doi.org/10.1002/acr.21753
Article CAS Google Scholar
Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P (2006) Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin 127(18):697–701. https://doi.org/10.1016/s0025-7753(06)72367-3
Article Google Scholar
Mathiesen PR, Buchvald F, Nielsen KG, Herlin T, Friis T, Nielsen S (2014) Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford) 53(4):644–649. https://doi.org/10.1093/rheumatology/ket380
Article CAS Google Scholar
McCann LJ, Garay SM, Ryan MM, Harris R, Riley P, Pilkington CA (2007) Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology (Oxford) 46(8):1363–1366. https://doi.org/10.1093/rheumatology/kem131
Article CAS Google Scholar
McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, Pilkington CA, Juvenile Dermatomyositis Research G (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 45(10):1255–1260. https://doi.org/10.1093/rheumatology/kel099
Article CAS Google Scholar
McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW (2018) Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis 77(2):241–250. https://doi.org/10.1136/annrheumdis-2017-212141
Article PubMed Google Scholar
McMillan HJ, Michaud J (2013) Inflammatory changes in limb girdle muscular dystrophy type 2I. Can J Neurol Sci 40(6):875–877. https://doi.org/10.1017/s0317167100016061
Article CAS PubMed Google Scholar
Mercer LK, Moore TL, Chinoy H, Murray AK, Vail A, Cooper RG, Herrick AL (2010) Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 49(9):1699–1705. https://doi.org/10.1093/rheumatology/keq051
Article Google Scholar
Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 54(1):50–63. https://doi.org/10.1093/rheumatology/keu289
Article CAS Google Scholar
Miles L, Bove KE, Lovell D, Wargula JC, Bukulmez H, Shao M, Salisbury S, Bean JA (2007) Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 57(7):1183–1191. https://doi.org/10.1002/art.22993
Article CAS PubMed Google Scholar
Miller FW, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O‘Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, O‘Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI, Gregersen PK, Myositis Genetics C (2013) Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 65(12):3239–3247. https://doi.org/10.1002/art.38137
Article CAS PubMed PubMed Central Google Scholar
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, International Myositis Outcome Assessment Collaborative Study G (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40(11):1262–1273. https://doi.org/10.1093/rheumatology/40.11.1262
Article CAS Google Scholar
Miller G, Heckmatt JZ, Dubowitz V (1983) Drug treatment of juvenile dermatomyositis. Arch Dis Child 58(6):445–450. https://doi.org/10.1136/adc.58.6.445
Article CAS PubMed PubMed Central Google Scholar
Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV (2019) Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford) 58(6):1011–1015. https://doi.org/10.1093/rheumatology/key366
Article Google Scholar
Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, Minetti C, Bracci-Laudiero L, Ravelli A, De Benedetti F, Nicolai R (2019) Muscle expression of type i and type ii interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol 71(6):1011–1021. https://doi.org/10.1002/art.40800
Article CAS PubMed Google Scholar
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R, Investigators T-T (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221. https://doi.org/10.1056/NEJMoa1912196
Article CAS PubMed Google Scholar
Morris P, Dare J (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32(3):189–191. https://doi.org/10.1097/MPH.0b013e3181bf29a2
Article PubMed Google Scholar
Neely J, Long CS, Sturrock H, Kim S, Investigators CR (2019) The association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23840
Norton WL, Velayos E, Robison L (1970) Endothelial inclusions in dermatomyositis. Ann Rheum Dis 29(1):67–72. https://doi.org/10.1136/ard.29.1.67
Article CAS PubMed PubMed Central Google Scholar
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, Group RIMS (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324. https://doi.org/10.1002/art.37754
Article CAS PubMed PubMed Central Google Scholar
Olson NY, Lindsley CB (1989) Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16(12):1545–1547
CAS PubMed Google Scholar
Omori CH, Silva CA, Sallum AM, Rodrigues Pereira RM, Luciade Sa Pinto A, Roschel H, Gualano B (2012) Exercise training in juvenile dermatomyositis. Arthritis Care Res 64(8):1186–1194. https://doi.org/10.1002/acr.21684
Article CAS Google Scholar
Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346(8):570–578. https://doi.org/10.1056/NEJMoa012437
Article CAS PubMed Google Scholar
Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM (2010) Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis Rheum 62(5):1533–1538. https://doi.org/10.1002/art.27379
Article PubMed PubMed Central Google Scholar
Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray L, Ramsey-Goldman R (2006) Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 148(2):247–253. https://doi.org/10.1016/j.jpeds.2005.10.032
Article PubMed Google Scholar
Pachman LM, Callan AM, Hayford J, Chung A, Sinacore JM, Ramsey-Goldman R (1994) Juvenile dermatomyositis: decreased calcinosis (Ca⁺⁺) with intermittent high-dose intravenous methylprednisolone (IV pulse) therapy. Arthritis Rheum 37(9 Suppl):S429
Google Scholar
Pachman LM, Khojah AM (2018) Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr 195:16–27. https://doi.org/10.1016/j.jpeds.2017.12.053
Article PubMed PubMed Central Google Scholar
Paik JJ, Christopher-Stine L (2017) A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum 46(4):e19. https://doi.org/10.1016/j.semarthrit.2016.08.009
Article PubMed Google Scholar
Papa V, Romanin B, Bergamaschi R, Cordelli DM, Costa R, De Giorgi LB, Cenacchi G (2016) Juvenile dermatomyositis: A report of three cases. Ultrastruct Pathol 40(2):83–85. https://doi.org/10.3109/01913123.2016.1141823
Article CAS PubMed Google Scholar
Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D (2019) Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain J Neurol 142(3):e8. https://doi.org/10.1093/brain/awz005
Article Google Scholar
Papadopoulou C, McCann LJ (2018) The vasculopathy of juvenile dermatomyositis. Front Pediatr 6:284. https://doi.org/10.3389/fped.2018.00284
Article PubMed PubMed Central Google Scholar
Park JH, Niermann KJ, Ryder NM, Nelson AE, Das A, Lawton AR, Hernanz-Schulman M, Olsen NJ (2000) Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. Arthritis Rheum 43(10):2359–2367. https://doi.org/10.1002/1529-0131(200010)43:10<2359::AID-ANR25>3.0.CO;2-D
Article CAS PubMed Google Scholar
Parks CG, Wilkerson J, Rose KM, Faiq A, Noroozi Farhadi P, Long CS, Bayat N, Brunner HI, Goldberg B, McGrath JA, Miller FW, Rider LG (2019) Association of ultraviolet radiation exposure with dermatomyositis in a National Myositis Patient Registry. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.24059
Phillips R, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M (2009) Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Zugegriffen am 24.02.2020
Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, Neve V, Thumerelle C, Quartier P, Tillie-Leblond I (2013) The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol 48(10):1016–1025. https://doi.org/10.1002/ppul.22742
Article PubMed Google Scholar
Quinones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM (2013) Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Arthritis Care Res (Hoboken) 65(10):1697–1701. https://doi.org/10.1002/acr.22041
Article Google Scholar
Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, Cameron B, Spiegel L, Schneider R, Laxer RM, Silverman ED, Feldman BM (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52(11):3570–3578. https://doi.org/10.1002/art.21378
Article CAS PubMed Google Scholar
Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62(1):63–72. https://doi.org/10.1002/acr.20015
Article Google Scholar
Reichlin M, Mattioli M (1976) Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 5(1):12–20. https://doi.org/10.1016/0090-1229(76)90145-8
Article CAS PubMed Google Scholar
Rice GI, Melki I, Fremond ML, Briggs TA, Rodero MP, Kitabayashi N, Oojageer A, Bader-Meunier B, Belot A, Bodemer C, Quartier P, Crow YJ (2017) Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol 37(2):123–132. https://doi.org/10.1007/s10875-016-0359-1
Article CAS PubMed Google Scholar
Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N (2017) 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 69(5):911–923. https://doi.org/10.1002/art.40060
Article CAS PubMed PubMed Central Google Scholar
Rider LG, Atkinson JC (2009) Images in clinical medicine. Gingival and periungual vasculopathy of juvenile dermatomyositis. N Engl J Med 360(15):e21. https://doi.org/10.1056/NEJMicm062850
Article CAS PubMed PubMed Central Google Scholar
Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010a) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 62(4):465–472. https://doi.org/10.1002/acr.20035
Article Google Scholar
Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW, Group I (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60(11):3425–3435. https://doi.org/10.1002/art.24904
Article PubMed PubMed Central Google Scholar
Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, Rennebohm RM, Passo MH, Summers RM, Hicks JE, Lachenbruch PA, Heyes MP, Miller FW, Juvenile Dermatomyositis Disease Activity Collaboration Study G (2002) Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 48(10):1681–1688
CAS PubMed Google Scholar
Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, Childhood Myositis Heterogeneity Collaborative Study G (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243. https://doi.org/10.1097/MD.0b013e31829d08f9
Article CAS Google Scholar
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63(Suppl 11):118–157. https://doi.org/10.1002/acr.20532
Article Google Scholar
Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW, Childhood Myositis Heterogeneity Collaborative Study G (2010b) Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 49(12):2381–2390. https://doi.org/10.1093/rheumatology/keq277
Article Google Scholar
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47(6):877–880. https://doi.org/10.1093/rheumatology/ken074
Article CAS Google Scholar
Robinson AB, Reed AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7(11):664–675. https://doi.org/10.1038/nrrheum.2011.139
Article CAS PubMed Google Scholar
Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE (2012) Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr 160(2):297–302. https://doi.org/10.1016/j.jpeds.2011.08.011
Article CAS PubMed Google Scholar
Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, McGlasson SL, Alyanakian MA, Bader-Meunier B, Barnerias C, Bellon N, Belot A, Bodemer C, Briggs TA, Desguerre I, Fremond ML, Hully M, van den Maagdenberg A, Melki I, Meyts I, Musset L, Pelzer N, Quartier P, Terwindt GM, Wardlaw J, Wiseman S, Rieux-Laucat F, Rose Y, Neven B, Hertel C, Hayday A, Albert ML, Rozenberg F, Crow YJ, Duffy D (2017) Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med 214(5):1547–1555. https://doi.org/10.1084/jem.20161451
Article CAS PubMed PubMed Central Google Scholar
Rose AL (1974) Childhood polymyositis. A follow-up study with special reference to treatment with corticosteroids. Am J Dis Child 127(4):518–522. https://doi.org/10.1001/archpedi.1974.02110230064009
Article CAS PubMed Google Scholar
Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 66(5):783–787. https://doi.org/10.1002/acr.22198
Article CAS Google Scholar
Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM (2010) Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 62(10):1446–1451. https://doi.org/10.1002/acr.20269
Article Google Scholar
Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113(8):619–627. https://doi.org/10.7326/0003-4819-113-8-619
Article CAS PubMed Google Scholar
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A, Paediatric Rheumatology International Trials O (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387(10019):671–678. https://doi.org/10.1016/S0140-6736(15)01021-1
Article PubMed Google Scholar
Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A, Paediatric Rheumatology International Trials O, Pediatric Rheumatology Collaborative Study G (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 42(12):1452–1459. https://doi.org/10.1093/rheumatology/keg403
Article Google Scholar
Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, Carrasco R, Rosenzweig S, Goldbach-Mansky R, Rider LG (2019) Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain J Neurol 142(11):e59. https://doi.org/10.1093/brain/awz293
Article Google Scholar
Saini I, Kalaivani M, Kabra SK (2016) Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 36(7):961–965. https://doi.org/10.1007/s00296-016-3467-6
Article CAS PubMed Google Scholar
Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119. https://doi.org/10.2174/157339710791330740
Article PubMed PubMed Central Google Scholar
Sakurai N, Hino-Shishikura A, Nozawa T, Kamide H, Ohara A, Nishimura K, Kikuchi M, Hara R, Mori M, Ito S (2019) Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. Mod Rheumatol 29(5):808–813. https://doi.org/10.1080/14397595.2018.1511026
Article CAS PubMed Google Scholar
Sanner H, Aalokken TM, Gran JT, Sjaastad I, Johansen B, Flato B (2011) Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70(1):86–91. https://doi.org/10.1136/ard.2010.131433
Article PubMed Google Scholar
Sansome A, Dubowitz V (1995) Intravenous immunoglobulin in juvenile dermatomyositis – four year review of nine cases. Arch Dis Child 72(1):25–28. https://doi.org/10.1136/adc.72.1.25
Article CAS PubMed PubMed Central Google Scholar
Sarkar K, Weinberg CR, Oddis CV, Medsger TA Jr, Plotz PH, Reveille JD, Arnett FC, Targoff IN, Genth E, Love LA, Miller FW (2005) Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum 52(8):2433–2438. https://doi.org/10.1002/art.21198
Article PubMed Google Scholar
Scheja A, Elborgh R, Wildt M (1999) Decreased capillary density in juvenile dermatomyositis and in mixed connective tissue disease. J Rheumatol 26(6):1377–1381
CAS PubMed Google Scholar
Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, Stringer E, Feldman BM (2011) Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 50(5):885–893. https://doi.org/10.1093/rheumatology/keq407
Article Google Scholar
Schutz PW, Scalco RS, Barresi R, Houlden H, Parton M, Holton JL (2017) Calpainopathy with macrophage-rich, regional inflammatory infiltrates. Neuromuscul Disord 27(8):738–741. https://doi.org/10.1016/j.nmd.2017.04.012
Article PubMed Google Scholar
Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H (2016) Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2(2):e000291. https://doi.org/10.1136/rmdopen-2016-000291
Article PubMed PubMed Central Google Scholar
Shah M, Targoff IN, Rice MM, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G (2013) Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 65(7):1934–1941. https://doi.org/10.1002/art.37985
Article CAS PubMed PubMed Central Google Scholar
Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM (2010) Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 62(9):2813–2822. https://doi.org/10.1002/art.27529
Article PubMed PubMed Central Google Scholar
Silver RM, Maricq HR (1989) Childhood dermatomyositis: serial microvascular studies. Pediatrics 83(2):278–283
CAS PubMed Google Scholar
Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM (2004) Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 31(8):1644–1649
PubMed Google Scholar
Smolen JS (2019) Treat to target in rheumatology: a historical account on occasion of the 10^th anniversary. Rheum Dis Clin North Am 45(4):477–485. https://doi.org/10.1016/j.rdc.2019.07.001
Article PubMed Google Scholar
Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 66(4):775–782. https://doi.org/10.1002/art.38323
Article PubMed PubMed Central Google Scholar
Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK (1984) Course of treated juvenile dermatomyositis. J Pediatr 105(3):399–408. https://doi.org/10.1016/s0022-3476(84)80012-8
Article CAS PubMed Google Scholar
Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A, Pediatric Rheumatologist C (2017) Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J 15(1):50. https://doi.org/10.1186/s12969-017-0174-0
Article CAS PubMed PubMed Central Google Scholar
Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1):41–45. https://doi.org/10.1054/bjoc.2001.1699
Article CAS PubMed PubMed Central Google Scholar
Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM (2010) Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 37(9):1953–1961. https://doi.org/10.3899/jrheum.090953
Article CAS PubMed Google Scholar
Stringer E, Singh-Grewal D, Feldman BM (2008) Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 58(11):3585–3592. https://doi.org/10.1002/art.23960
Article PubMed Google Scholar
Sullivan DB, Cassidy JT, Petty RE, Burt A (1972) Prognosis in childhood dermatomyositis. J Pediatr 80(4):555–563. https://doi.org/10.1016/s0022-3476(72)80050-7
Article CAS PubMed Google Scholar
Sultan SM (2003) The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy. Curr Rheumatol Rep 5(6):445–450. https://doi.org/10.1007/s11926-003-0055-z
Article PubMed Google Scholar
Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ, Group UKJDR (2014a) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16(4):R138. https://doi.org/10.1186/ar4600
Article CAS PubMed PubMed Central Google Scholar
Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ, Juvenile Dermatomyositis Research G (2014b) Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 53(12):2204–2208. https://doi.org/10.1093/rheumatology/keu259
Article Google Scholar
Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, Warrier K, Wedderburn LR, McHugh NJ (2017a) Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients. J Rheumatol 44(4):488–492. https://doi.org/10.3899/jrheum.160871
Article PubMed Google Scholar
Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ (2017b) Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 84:55–64. https://doi.org/10.1016/j.jaut.2017.06.007
Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, Johnson K, Kraft J, Landes C, Persaud T, Sinha R, Offiah AC (2018) Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. Rheumatology (Oxford) 57(9):1661–1668. https://doi.org/10.1093/rheumatology/key144
Article CAS Google Scholar
Tiidus PM, Ianuzzo CD (1983) Effects of intensity and duration of muscular exercise on delayed soreness and serum enzyme activities. Med Sci Sports Exerc 15(6):461–465
Article CAS PubMed Google Scholar
Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL (2017) More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 56(5):787–794. https://doi.org/10.1093/rheumatology/kew470
Article CAS Google Scholar
Tournadre A, Dubost JJ, Soubrier M, Ruivard M, Souteyrand P, Schmidt J, Clavelou P, Tridon A, Ristori JM (2014) Soluble IL-2 receptor: a biomarker for assessing myositis activity. Dis Markers 2014:472624. https://doi.org/10.1155/2014/472624
Article CAS PubMed PubMed Central Google Scholar
Trapani S, Camiciottoli G, Vierucci A, Pistolesi M, Falcini F (2001) Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford) 40(2):216–220. https://doi.org/10.1093/rheumatology/40.2.216
Article CAS Google Scholar
Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, Silverman ED, Schneider R, Feldman BM (2001) The arthritis of inflammatory childhood myositis syndromes. J Rheumatol 28(1):192–197
CAS PubMed Google Scholar
Unverricht H (1891) Dermatomyositis acuta. Dtsch Med Wochenschr 17:41–44
Article Google Scholar
Urganus AL, Zhao YD, Pachman LM (2009) Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum 61(4):501–508. https://doi.org/10.1002/art.24391
Article PubMed PubMed Central Google Scholar
Vedanarayanan V, Subramony SH, Ray LI, Evans OB (1995) Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 13(4):336–339. https://doi.org/10.1016/0887-8994(95)00195-6
Article CAS PubMed Google Scholar
Verma S, Singh S, Bhalla AK, Khullar M (2006) Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum 55(4):564–568. https://doi.org/10.1002/art.22108
Article PubMed Google Scholar
Wagner E (1863) Fall einer seltnen Muskelerkrankung. Arch Heilkd 4:282–283
Google Scholar
Wedgwood RJ, Cook CD, Cohen J (1953) Dermatomyositis; report of 26 cases in children with a discussion of endocrine therapy in 13. Pediatrics 12(4):447–466
CAS PubMed Google Scholar
Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, Voll RE, Thiel J (2019) Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib – A report of two cases. J Autoimmun 100:131–136. https://doi.org/10.1016/j.jaut.2019.03.003
Article CAS PubMed Google Scholar
Winzenberg T, Jones G (2013) Vitamin D and bone health in childhood and adolescence. Calcif Tissue Int 92(2):140–150. https://doi.org/10.1007/s00223-012-9615-4
Article CAS PubMed Google Scholar
Wolf SJ, Estadt SN, Gudjonsson JE, Kahlenberg JM (2018) Human and murine evidence for mechanisms driving autoimmune photosensitivity. Front Immunol 9:2430. https://doi.org/10.3389/fimmu.2018.02430
Article CAS PubMed PubMed Central Google Scholar
Xu C, Chen J, Zhang Y, Li J (2018) Limb-girdle muscular dystrophy type 2B misdiagnosed as polymyositis at the early stage: Case report and literature review. Medicine (Baltimore) 97(21):e10539. https://doi.org/10.1097/MD.0000000000010539
Article Google Scholar
Yasin SA, Schutz PW, Deakin CT, Sag E, Varsani H, Simou S, Marshall LR, Tansley SL, NJ MH, Holton JL, Wedderburn LR, Jacques TS, Group UKJDR (2019) Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 45(5):495–512. https://doi.org/10.1111/nan.12528
Article CAS PubMed PubMed Central Google Scholar

Download references

Author information

Authors and Affiliations

Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster, Deutschland
Claas Hinze
Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
Angelika Thon

Authors

Claas Hinze
View author publications
You can also search for this author in PubMed Google Scholar
Angelika Thon
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claas Hinze .

Editor information

Editors and Affiliations

Universitätsklinikum Aachen Klinik für Kinder- und Jugendmedizin, Aachen, Germany
Norbert Wagner
15306 Seelow, Germany
Günther Dannecker
Kinderklinik, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany
Tilmann Kallinich

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Cite this entry

Hinze, C., Thon, A. (2021). Dermatomyositis bei Kindern und Jugendlichen. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60411-3_40-1

Download citation

DOI: https://doi.org/10.1007/978-3-662-60411-3_40-1
Received: 28 December 2020
Accepted: 29 January 2021
Published: 29 April 2021
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60411-3
Online ISBN: 978-3-662-60411-3
eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics